1. Biology of Blood and Marrow Transplantation
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia 
David I. Marks, MB, PhD, FRACP, FRCPath, Partow Kebriaei, MD, Matthias Stelljes, MD, Nicola Gökbuget, MD, Hagop Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Tao Wang, PhD, Hui Zhang, PhD, Fausto Loberiza, MD, MS, Erik Vandendries, MD, PhD, Daniel J. DeAngelo, MD, PhD 
Biology of Blood and Marrow Transplantation 
DOI: /j.bbmt
Copyright © 2019 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Trial profile.
Biology of Blood and Marrow Transplantation DOI: ( /j.bbmt )
Copyright © 2019 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Kaplan-Meier plots of post-transplant progression-free survival and (B) post-transplant overall survival for patients treated with InO and SC.
Biology of Blood and Marrow Transplantation DOI: ( /j.bbmt )
Copyright © 2019 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Kaplan-Meier plot of post-transplant survival for subgroups of patients who received InO (intent-to-treat [ITT] population) and proceeded to allogeneic follow-up HSCT. (A) All InO-treated patients in Studies 1010 and 1022 who had post-treatment allogeneic HSCT. (B) Subset of these InO-treated patients who did not have previous HSCT. (C) Subset of these InO-treated patients who had no previous HSCT and proceeded to HSCT in CR/CRi.
Biology of Blood and Marrow Transplantation DOI: ( /j.bbmt )
Copyright © 2019 American Society for Blood and Marrow Transplantation Terms and Conditions